Lundbeck Seeks Approval For A Novel Alcoholism Treatment

Danish drugmaker Lundbeck has submitted a marketing authorisation application (MAA) through the centralised procedure to the European Medicines Agency (EMA) for Selincro (nalmefene), a novel opioid receptor ligand for the reduction of alcohol consumption in patients with alcohol dependence. Lundbeck originally licensed the rights for Selincro from Biotie Therapeutics in 2006 for a number of markets and has since expanded the agreement to cover worldwide rights. Biotie received an execution fee of EUR12mn (US$15.6mn) and is eligible to receive up to EUR84mn in upfront and milestone payments, plus royalties on sales. Lundbeck will be responsible for the manufacturing and registration

To read the full article, please choose one of the following options: